共 237 条
[1]
Wei SC(2018)Fundamental mechanisms of immune checkpoint blockade therapy Cancer Discov 8 1069-1086
[2]
Duffy CR(2021)Hallmarks of response, resistance, and toxicity to immune checkpoint blockade Cell 184 5309-5337
[3]
Allison JP(2017)Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer N Engl J Med 377 1919-1929
[4]
Morad G(2018)Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 379 2342-2350
[5]
Helmink BA(2021)Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial J Thorac Oncol 16 860-867
[6]
Sharma P(2009)Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment Blood 114 589-595
[7]
Antonia SJ(2012)Radiotherapy promotes tumor-specific effector CD8 + T cells via dendritic cell activation J Immunol 189 558-566
[8]
Villegas A(2019)Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation J Clin Invest 129 4224-4238
[9]
Daniel D(2020)Dendritic cell maturation defines immunological responsiveness of tumors to radiation therapy J Immunol 204 3416-3424
[10]
Antonia SJ(2017)In situ vaccination after accelerated hypofractionated radiation and surgery in a mesothelioma mouse model Clin Cancer Res 23 5502-5513